OnabotulinumtoxinA 145 UNT [Botox]
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Drug-resistant Focal Seizure
Conditions
Drug-resistant Focal Seizure
Trial Timeline
Mar 1, 2023 → Dec 1, 2024
NCT ID
NCT05605756About OnabotulinumtoxinA 145 UNT [Botox]
OnabotulinumtoxinA 145 UNT [Botox] is a approved stage product being developed by AbbVie for Drug-resistant Focal Seizure. The current trial status is terminated. This product is registered under clinical trial identifier NCT05605756. Target conditions include Drug-resistant Focal Seizure.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05605756 | Approved | Terminated |
Competing Products
6 competing products in Drug-resistant Focal Seizure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid | Novartis | Phase 2 | 52 |
| UCB0942 | UCB | Phase 2 | 49 |
| Padsevonil + Placebo | UCB | Phase 3 | 74 |
| Padsevonil | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |
| Padsevonil | UCB | Phase 2 | 49 |